Partnership leverages Bruno Farmaceutici’s robust commercial leadership to launch Althera’s innovative Type 2 Diabetes combination therapy
DUBLIN, DUBLIN, IRELAND, January 30, 2026 /EINPresswire.com/ -- Althera Laboratories Limited, a global pharmaceutical company focused on developing value-added cardiovascular and metabolic medicines, and Bruno Farmaceutici S.p.A., a leading Italian pharmaceutical company, today announced the signing of an licensing and supply agreement.
Under the terms of the agreement, Bruno Farmaceutici is granted the rights to market and
